More, earlier damage seen in primary progressive MS vs SPMS
People with primary progressive multiple sclerosis (MS) may experience more severe inflammatory activity and nerve damage early on in…
Articles by Marisa Wexler, MS
New wearable microscope can help image cell activity in mice
A team of scientists has developed a wearable microscope — to be carried on the backs of animals in a…
Experts call for testing for PML risk genes to guide MS treatments
A pair of experts are calling for genetic tests to be developed to identify people at higher risk of developing…
‘A Campbell Never Quits’ podcast coming in March for MS awareness
A new podcast series called “A Campbell Never Quits” is telling the life story of Tyler Campbell, a patient advocate…
Analyzing MS brain scans could further research into COVID-19
Because people with multiple sclerosis (MS) usually undergo regular MRI scans to image their brains, their data could…
Treatments with electrical nerve stimulation ease pain in small trial
Transcutaneous electrical nerve stimulation (TENS) and interferential currents (IFC) — both interventions apply electrical stimulation through electrodes placed on the…
Stem cell therapy MSC-NP can ease inflammatory activity in brain cells
MSC-NP, a form of stem cell therapy that’s currently in early clinical trials for multiple sclerosis (MS), can reduce…
Ocrevus and early start with aggressive treatment favored in US
Neurologists in the U.S. are generally favoring more aggressive early treatment for multiple sclerosis (MS), according to an…
ACTRIMS 2023: Can Do MS brings education, connection, activation
Can Do MS has three missions for people with multiple sclerosis (MS) and their care partners — providing…
ACTRIMS 2023: Delays in Ocrevus infusions not tied to greater MS activity
People with multiple sclerosis (MS) being treated with Ocrevus (ocrelizumab) less frequently than the recommended every six months…
ACTRIMS 2023: TG aims to make Briumvi accessible to patients
Briumvi (ublituximab-xiiy) recently became the third anti-CD20 monoclonal antibody to be approved by the U.S. Food and Drug Administration…
ACTRIMS 2023: Ibudilast did not lift life quality in progressive MS trial
Treatment with the experimental oral therapy ibudilast (MN-166) does not significantly improve quality-of-life measures compared with a placebo among…
ACTRIMS 2023: High-dose vitamin D doesn’t reduce MS activity: Trial
Taking high-dose vitamin D supplements as an add-on to standard MS treatment doesn’t reduce the risk of inflammatory…
ACTRIMS 2023: Certain eye cells tied to MS-related changes in study
Certain cells in the eyes — specifically blood vessel cells and a type of neurological immune cell called…
ACTRIMS 2023: Most on Briumvi show no MS activity after 6 months
More than half of the people with relapsing forms of multiple sclerosis (MS) who received Briumvi (ublituximab) in…
ACTRIMS 2023: HIV-positive people found to be less likely to develop MS
People infected with the human immunodeficiency virus (HIV) — including HIV-positive individuals who received antiretroviral treatment at some…
ACTRIMS 2023: MS clinical research lacks diversity, representation
Nonwhite populations are underrepresented in research that tests therapies for multiple sclerosis (MS), meaning most available data on a…
ACTRIMS 2023: CNM-Au8 bound for Phase 3 testing after positive data
Treatment with the experimental oral suspension therapy CNM-Au8 led to improvements in measures of vision, cognitive and motor function,…
ACTRIMS 2023: Should EBV be targeted in MS? Experts debate.
A history of infection with Epstein-Barr virus (EBV) has been shown to be a strong risk factor for developing…
ACTRIMS 2023: Portable MRI device able to detect brain lesions in MS
A portable MRI device may be used to detect brain lesions that are indicative of multiple sclerosis (MS), and…
ACTRIMS 2023: Medication, talk therapy both ease MS-related fatigue
Cognitive behavioral therapy (CBT), a form of talk therapy, and medication given separately or in combination can ease fatigue significantly…
Omega-3 fatty acid reduced disease severity in MS mouse model
Treatment with docosahexaenoyl ethanolamide (DHEA), an omega-3 fatty acid found in fish oil, reduced inflammation and disease severity in a…
CNM-Au8 preserves white matter in RRMS patients’ brains: Phase 2 trial
Treatment with CNM-Au8, an experimental oral liquid therapy, led to statistically significant improvements in the health of connections between brain regions…
‘Mini-brain’ models point to poorer oligodendrocyte growth in PPMS
Using stem cells derived from people with multiple sclerosis (MS), researchers developed cerebral organoids, or “mini-brains,” to better study…
Levels of GFAP protein in blood may predict ‘silent progression’ of MS
Measuring levels of the protein GFAP in blood can help to predict disability progression that occurs without relapses — so-called…
Berberine, plant compound, eases disease severity in MS mouse model
Treatment with berberine, a compound found in many plants, eased disease severity and showed anti-inflammatory effects in a mouse model…
Primary progressive MS confirmed as own disorder in mouse study
Primary progressive multiple sclerosis (PPMS) is driven by antibodies in the cerebrospinal fluid (CSF), the liquid around the brain…
Biosimilar Comparable in Safety, Efficacy to Tysabri in Phase 3 Trial
PB006, a biosimilar to Biogen’s approved treatment Tysabri (natalizumab), showed similar safety and efficacy as the original medication…
Hi-res MRI Scanners May Bring MS’s Effect on the Cerebellum Into View
Researchers were able to image the cerebellum — a small, compact region of the brain that plays key roles in…
Better Standards Needed for NICE Evaluation of MS Treatments: Study
In evaluating potential treatments for multiple sclerosis (MS) over the past two decades, England’s National Institute for Health and…